Without issuing an opinion, the U.S. Court of Appeals for the Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) decision invaliding three patents (Nos. 8,889,135, 9,017,680 and 9,073,987) covering AbbVie’s (ABBV -0.5%) top seller Humira (adalimumab).
The patents were challenged by Coherus BioSciences (CHRS -1%) and privately held Boehringer Ingelheim, both of which have already settled with AbbVie.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.